Shanghai Jinhe Bio-Technology

Shanghai Jinhe Bio-Technology is a China-based pharmaceutical company focused on the development, manufacturing, and marketing of anticancer active pharmaceutical ingredients and intermediates. The company appears to specialize in plant-derived and semisynthetic oncology APIs, particularly taxanes and camptothecin-related products. Publicly available company and distributor profiles indicate products including paclitaxel, docetaxel, cabazitaxel, irinotecan hydrochloride trihydrate, etoposide, palonosetron hydrochloride, and intermediates such as 10-deacetylbaccatin III. Jinhe was established in 2002 and reportedly became part of Shanghai Pharma in January 2012. Based on the available evidence, the business is a commercial manufacturer/supplier rather than a clinical-stage drug developer, with exports to international markets.